Last reviewed · How we verify
IHL-42X Low Dose
IHL-42X Low Dose is a Small molecule drug developed by Incannex Healthcare Ltd. It is currently in Phase 2 development. Also known as: Phase 2 Investigational Product - IHL-42X Low dose.
At a glance
| Generic name | IHL-42X Low Dose |
|---|---|
| Also known as | Phase 2 Investigational Product - IHL-42X Low dose |
| Sponsor | Incannex Healthcare Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IHL-42X Low Dose CI brief — competitive landscape report
- IHL-42X Low Dose updates RSS · CI watch RSS
- Incannex Healthcare Ltd portfolio CI
Frequently asked questions about IHL-42X Low Dose
What is IHL-42X Low Dose?
IHL-42X Low Dose is a Small molecule drug developed by Incannex Healthcare Ltd.
Who makes IHL-42X Low Dose?
IHL-42X Low Dose is developed by Incannex Healthcare Ltd (see full Incannex Healthcare Ltd pipeline at /company/incannex-healthcare-ltd).
Is IHL-42X Low Dose also known as anything else?
IHL-42X Low Dose is also known as Phase 2 Investigational Product - IHL-42X Low dose.
What development phase is IHL-42X Low Dose in?
IHL-42X Low Dose is in Phase 2.
Related
- Manufacturer: Incannex Healthcare Ltd — full pipeline
- Also known as: Phase 2 Investigational Product - IHL-42X Low dose
- Compare: IHL-42X Low Dose vs similar drugs
- Pricing: IHL-42X Low Dose cost, discount & access